

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1.-4. *(Cancelled).*

5. *(Currently amended)* A method of reducing the risk of insulin-induced preventing hypoglycemia in a diabetes patient who is being treated with insulin, which method comprises administering a basal replacement dose of glucagon to a patient and who is not suffering hypoglycemic symptoms which method comprises administering glucagon to said patient in an amount therapeutically effective for the prevention of hypoglycemia.

6. *(Original)* The method of claim 5, wherein said glucagon is administered simultaneously with, or within one minute to four hours after said patient has last been administered insulin.

7. *(Cancelled).*

8. *(Currently amended)* The method of claim 5 2, wherein said insulin is administered parenterally and said glucagon is administered by a route of administration selected from the group consisting of oral administration, ocular administration, nasal administration, pulmonary administration, parenteral administration, and transdermal administration parenterally by a subcutaneous, intramuscular, or intravenous route.

9. *(Currently amended)* The method of claim 5 8, wherein the patient has a blood glucose level of from 70 - 110 mg/dL said glucagon is administered transdermally.

10. *(Original)* The method of claim 8, wherein said glucagon is a glucagon with a longer duration of action.

11. *(Cancelled).*

12. *(Original)* The method of claim 8, wherein said glucagon is contained in a liposomal formulation.

13. *(Original)* The method of claim 8, wherein said glucagon is contained in a microsphere.

14.-17. *(Cancelled).*

18. *(New)* The method of claim 5 wherein the basal replacement dose of glucagon results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 3.00 ng/kg/min.

19. *(New)* The method of claim 5 wherein glucagon is administered daily at bedtime.

20. *(New)* The method of claim 5 wherein the patient has a has a blood glucose level that is not less than 50 mg/dL.

21. *(New)* A method of reducing the risk of insulin-induced hypoglycemia in a diabetes patient who is being treated with insulin, which method comprises administering glucagon to the patient as part of a diabetes treatment regimen, wherein glucagon is administered daily at bedtime, wherein said patient is not suffering hypoglycemic symptoms.

22. *(New)* The method of claim 21 wherein the patient has a blood glucose level of from 70 - 110 mg/dL.

23. *(New)* The method of claim 21 wherein the patient has a has a blood glucose level that is not less than 50 mg/dL.

24. *(New)* The method of claim 21 in which a dose of glucagon is administered that results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 5.00 ng/kg/min.

25. *(New)* The method of claim 24 in which a dose of glucagon is administered that results in a plasma glucagon level in the range achieved by intravenous infusion of glucagon at a rate that is not less than 0.10 ng/kg/min and not more than 3.00 ng/kg/min.